Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M150,430Revenue $M24,890Net Margin (%)48.6Z-Score7.8
Enterprise Value $M153,099EPS $7.4Operating Margin %61.3F-Score8
P/E(ttm))13.7Cash Flow Per Share $4.3Pre-tax Margin (%)59.7Higher ROA y-yY
Price/Book9.910-y EBITDA Growth Rate %0Quick Ratio2.8Cash flow > EarningsY
Price/Sales6.75-y EBITDA Growth Rate %27.2Current Ratio3.1Lower Leverage y-yN
Price/Cash Flow17.4y-y EBITDA Growth Rate %246ROA % (ttm)41.6Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)86.6Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M1,489ROI % (ttm)15.0Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDJulian Robertson 2014-12-31 Add1.67%$89.45 - $114.22
($103.3)
$ 101.00-2%Add 20.27%533,911
GILDLeon Cooperman 2014-12-31 Buy 0.96%$89.45 - $114.22
($103.54)
$ 101.00-3%New holding612,500
GILDJean-Marie Eveillard 2014-12-31 Add0.3%$89.45 - $114.22
($103.4)
$ 101.00-2%Add 328672.00%1,315,088
GILDJoel Greenblatt 2014-12-31 Add0.26%$89.45 - $114.22
($103.3)
$ 101.00-2%Add 51.98%1,009,462
GILDRonald Muhlenkamp 2014-12-31 Add0.24%$89.45 - $114.22
($103.4)
$ 101.00-2%Add 6.10%218,945
GILDRay Dalio 2014-12-31 Add0.22%$89.45 - $114.22
($103.4)
$ 101.00-2%Add 122.47%537,321
GILDJohn Rogers 2014-12-31 Add0.17%$89.45 - $114.22
($103.4)
$ 101.00-2%Add 24.68%802,803
GILDJohn Burbank 2014-12-31 Add0.06%$89.45 - $114.22
($103.3)
$ 101.00-2%Add 212.68%37,750
GILDKen Heebner 2014-12-31 Sold Out -4.7%$89.45 - $114.22
($103.4)
$ 101.00-2%Sold Out0
GILDVanguard Health Care Fund 2014-12-31 Sold Out -0.1%$89.45 - $114.22
($103.4)
$ 101.00-2%Sold Out0
GILDMariko Gordon 2014-12-31 Sold Out -0.05%$89.45 - $114.22
($103.3)
$ 101.00-2%Sold Out0
GILDDavid Dreman 2014-12-31 Sold Out -0.02%$89.45 - $114.22
($103.3)
$ 101.00-2%Sold Out0
GILDRonald Muhlenkamp 2014-09-30 Add1.19%$85.07 - $109.43
($97.98)
$ 101.003%Add 42.59%206,350
GILDKen Heebner 2014-09-30 Reduce-0.33%$85.07 - $109.43
($97.98)
$ 101.003%Reduce -8.77%1,560,000
GILDVanguard Health Care Fund 2014-09-30 Reduce-0.28%$85.07 - $109.43
($97.98)
$ 101.003%Reduce -76.79%379,200
GILDJoel Greenblatt 2014-09-30 Add0.21%$85.07 - $109.43
($97.98)
$ 101.003%Add 42.28%664,223
GILDRay Dalio 2014-09-30 Reduce-0.07%$85.07 - $109.43
($97.98)
$ 101.003%Reduce -30.96%241,521
GILDKen Fisher 2014-09-30 Reduce-0.04%$85.07 - $109.43
($97.98)
$ 101.003%Reduce -21.74%763,423
GILDDavid Dreman 2014-09-30 Buy 0.02%$85.07 - $109.43
($97.98)
$ 101.003%New holding2,388
GILDJohn Burbank 2014-09-30 Add0.01%$85.07 - $109.43
($97.98)
$ 101.003%Add 219.90%12,073
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BISCHOFBERGER NORBERT WEVP, R&D and CSO 2015-03-16Sell70,000$100.80.28view
MARTIN JOHN CChairman and CEO 2015-03-02Sell150,000$103.51-2.35view
Alton Gregg HEVP, Corp & Med Affairs 2015-03-02Sell12,000$103.63-2.46view
Carter Paul RutherfordEVP Commercial Ops 2015-03-02Sell2,000$104.18-2.98view
Whitley Richard JamesDirector 2015-03-02Sell5,000$103.43-2.27view
BISCHOFBERGER NORBERT WEVP, R&D and CSO 2015-02-17Sell70,000$103.01-1.87view
WOLD OLSEN PERDirector 2015-02-06Buy10,000$99.921.16view
Whitley Richard JamesDirector 2015-02-02Sell5,000$105.67-4.34view
MARTIN JOHN CChairman and CEO 2015-02-02Sell150,000$105.43-4.13view
Carter Paul RutherfordEVP Commercial Ops 2015-02-02Sell2,000$106.15-4.78view

Press Releases about GILD :

    Quarterly/Annual Reports about GILD:

    News about GILD:

    Articles On GuruFocus.com
    Analysts Remain Bullish on Gilead Despite Safety Warning Mar 24 2015 
    interested Mar 22 2015 
    Greenblatt's Top 3 Stakes for the Fourth Quarter Mar 13 2015 
    Gilead Taking Giant Leap To Serve The Hepatitis C Market Of Developing Countries Feb 26 2015 
    1 Feb 23 2015 
    1 Feb 23 2015 
    Tiger Management’s Julian Robertson Buys Apple, Netflix, Illumina, Sells Alibaba, EBay, MasTec Feb 17 2015 
    8 Strong Recommendations for 2015 Feb 13 2015 
    ? Feb 12 2015 
    Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 


    More From Other Websites
    GenFit NASH Data Drives Up Rival Intercept Mar 26 2015
    Midday Glance: Biotechnology companies Mar 26 2015
    A Bold Call on Biotech ETFs Mar 26 2015
    Biotech Stock Selloff: Is It Justified? Mar 26 2015
    Gilead Sciences: Big in Japan? Mar 26 2015
    Biotech Crash -- How Long Will It Last? Mar 26 2015
    The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex, Gilead and Amgen - Press Releases Mar 26 2015
    WHO urges Europeans to work together to counter high drug prices Mar 26 2015
    One analyst is convinced the biotech stock plunge is 'misguided' Mar 26 2015
    Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the... Mar 26 2015
    Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the... Mar 26 2015
    Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the... Mar 26 2015
    Biotech Stocks Deliver a Dose of Pain Mar 25 2015
    Read This Before You Sell Gilead Sciences Mar 25 2015
    Top 10 New Stocks to Trade Like Hedge Funds Renaissance Technologies Mar 25 2015
    US consumer stocks rise after Kraft and Heinz deal Mar 25 2015
    Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst... Mar 25 2015
    Why These Could Be 2015's 10 Best Biotech Stocks Mar 25 2015
    The 10 overseas shares most popular with British investors Mar 25 2015
    Why Deutsche Bank Says to Buy Gilead and Vertex Pullbacks Mar 25 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK